SCHEMBL7514048

SCHEMBL7514048

COc1cc2c(cc1OC)C(=O)C(C)(C)CC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CYP3A4 P08684 2/20 0.45
ALDH1A1 P00352 5/20 0.44
MAPT P10636 4/20 0.44
KDM4E B2RXH2 4/20 0.44
ACHE P22303 1/20 0.44
GAA P10253 1/20 0.44
MAOA P21397 1/20 0.44
MALT1 Q9UDY8 1/20 0.42
ABCB1 P08183 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 2/20 0.40
GLA P06280 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SLC2A1 P11166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26607327 0.89 MALT1 (0.40) MEN1KMT2ACA1CA2CA7
SCHEMBL26607151 0.89 MEN1 (0.39) MEN1KMT2ACA1CA2CA7
SCHEMBL8938822 0.82 ALDH1A1 (0.51) MEN1KMT2ACA1CA2CA7
SCHEMBL2819403 0.77 SMN1; SMN2 (0.51) CA1CA2CA7CA9CYP3A4
SCHEMBL630002 0.77 SMN1; SMN2 (0.66) CA1CA2CA7CA9CYP3A4
SCHEMBL9588126 0.75 KDM1A (0.35) SMN1; SMN2MAPK1
SCHEMBL7424355 0.75 ACHE (0.38) MEN1KMT2ACYP3A4ALDH1A1MAPT
SCHEMBL23362041 0.75 HTR2A (0.44) MEN1KMT2ACA1CA2CA7
SCHEMBL6785200 0.74 MAPT (0.46) CYP3A4ALDH1A1MAPTKDM4EGAA
Hydrochloric Acid SCHEMBL7824196 0.72 MEN1 (0.40) MEN1KMT2ACA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1454203-A Substituted nitrated catechols, their use in the treatment of certain central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & CA SA (PT) 2003-11-05 CN disclosed
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US disclosed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 MEN1 1966/4885KMT2A 2898/4885CA1 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.